基于塑选择性蛋白酶体抑制剂的结构和功能设计
Hao Li1,2, Anthony J O'Donoghue3, Wouter A van der Linden1
1Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California 94305, USA.
Nature
|February 12, 2016
概括
研究人员开发了选择性蛋白酶抑制剂来治疗疟疾. 这些化合物向Plasmodium蛋白酶体,对抗药物耐药的寄生虫具有最小的宿主毒性,提供了一个有前途的新抗疟疾策略.
科学领域:
- 生物化学
- 寄生虫学
- 药物发现
背景情况:
- 蛋白质体调节重要的细胞过程,使其成为病原体治疗的目标.
- 蛋白酶抑制剂对疟疾寄生虫Plasmodium falciparum具有毒性.
- 现有的抑制剂缺乏选择性,影响寄生虫和宿主蛋白质体,限制治疗用途.
研究的目的:
- 确定用于选择性抑制剂开发的Plasmodium蛋白酶基质特异性和结构性质.
- 识别人类和Plasmodium falciparum蛋白酶体特异性的差异.
- 开发和验证选择性寄生虫蛋白酶抑制剂作为抗疟疾药物.
主要方法:
- 基质分析以比较人类和Plasmodium蛋白质组的特异性.
- 针对Plasmodium特定氨基酸偏好的抑制剂的设计.
- 低温电子显微镜测定与抑制剂结合的Plasmodium蛋白酶的结构.
- 在体外和体内测试抑制剂的有效性和毒性.
主要成果:
- 在人类和Plasmodium蛋白质体之间确定了不同的基质特异性.
- 开发了向Plasmodium蛋白酶β2亚单元的选择性抑制剂.
- 确定了Plasmodium蛋白质体的3.6 Å冷EM结构,揭示了一个开放的β2活性位点.
- 在体内无宿主毒性的情况下,证明了与素和寄生虫的协同增长抑制.
结论:
- 菌蛋白酶是疟疾的可行和选择性药物点.
- 选择性寄生虫抑制剂显示出新一代抗疟疾疗法的潜力.
- 对Plasmodium蛋白酶的结构洞察力有助于合理的抑制剂设计.
更多相关视频
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.6K
10:38High Yield Purification of Plasmodium falciparum Merozoites For Use in Opsonizing Antibody Assays
Published on: July 17, 2014
23.4K
相关概念视频
Diversity of Protists II
589
Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
589
Overview of Protists
868
Protists are diverse eukaryotic microorganisms that lack the specialized tissues of plants and animals and the chitinous cell walls of fungi. Their early divergence within Eukarya resulted in structural, functional, and ecological diversity. They are classified into supergroups such as Archaeplastida, Excavata, Amoebozoa, Rhizaria, Alveolata, and Stramenopiles, determined through genetic analysis and structural similarities.Structural and Functional AdaptationsProtists have various adaptations...
868
The Proteasome Structure
1.2K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.2K
The Proteasome
9.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.4K
The Proteasome
1.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.3K
